Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.06 USD
Change Today +0.0012 / 2.06%
Volume 1.2M
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Snapshot

Open
$0.06
Previous Close
$0.06
Day High
$0.06
Day Low
$0.05
52 Week High
05/5/14 - $0.19
52 Week Low
04/7/15 - $0.05
Market Cap
15.8M
Average Volume 10 Days
1.5M
EPS TTM
$-0.07
Shares Outstanding
265.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERNATIONAL STEM CELL CORP (ISCO)

international stem cell corp (ISCO) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCO) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCO) Details

International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and biomedical products worldwide. Its products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. The company develops cell types, such as neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat congenital and acquired liver diseases; islet cells for the treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. It also offers cosmetic skin care products through professional channels and distributors, as well as through a branded Website; and human cell culture products for use in pharmaceutical, academic, and government research organizations. The company’s human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines to study breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company offers its human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 03/30/15
Founded in 2001

international stem cell corp (ISCO) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $246.1K
Executive Vice President of Business Developm...
Total Annual Compensation: $220.0K
Chief Scientific Officer and Director
Total Annual Compensation: $196.9K
Compensation as of Fiscal Year 2014.

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Announces Resignation of Jay Novak as Chief Financial Officer, Effective May 8, 2015

On April 27, 2015, Jay Novak, the Chief Financial Officer of International Stem Cell Corporation announced his resignation from the Company, effective May 8, 2015. Mr. Novak is pursuing a new career opportunity in the biotechnology industry and has indicated that his resignation did not result from any disagreement with the Company's operations, policies or practices.

International Stem Cell Corporation Announces Consolidated Earnings Results for the Years Ended December 31, 2014

International Stem Cell Corporation announced consolidated earnings results for the years ended December 31, 2014. For the period, the company reported total revenue of $7,017,000 against $6,147,000 a year ago. Loss from operating activities was $8,680,000 against $7,546,000 a year ago. Loss before income taxes was $12,478,000 against $10,479,000 a year ago. Net loss was $12,478,000 against $10,479,000 a year ago. Net loss applicable to common stockholders was $12,478,000 against $10,479,000 a year ago. Net loss per basic &diluted share was $0.06 against $0.09 a year ago. invested $987,000 in capital and patent expenditures in 2014, up compared to $896,000 in the prior year.

International Stem Cell Corporation, Q4 2014 Earnings Call, Apr 01, 2015

International Stem Cell Corporation, Q4 2014 Earnings Call, Apr 01, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $0.06 USD +0.0012

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.23 USD +0.07
Bioheart Inc $0.0059 USD -0.0009
Cytori Therapeutics Inc $0.90 USD +0.0348
Nuo Therapeutics Inc $0.22 USD -0.0049
StemCells Inc $0.61 USD -0.0044
View Industry Companies
 

Industry Analysis

ISCO

Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 44.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit www.internationalstemcell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.